Maria-Elena Liosi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria-Elena Liosi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Hui Zhang
Yale University
1 shared publication - Israel Cabeza de Vaca
Yale University
1 shared publication - Joseph A. Ippolito
Yale University
1 shared publication - Julian Tirado-Rives
Yale University
1 shared publication - Karen S. Anderson
Department of Pharmacology
1 shared publication - Maya Deshmukh
Yale University School of Medicine
1 shared publication
Latest Publications
- Open Access
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
A consensus virtual screening protocol has been applied to ca. 2000 approved drugs to seek inhibitors of the main protease (M pro ) of SARS-CoV-2, the virus responsible for COVID-19. 42 drugs emerged as top candidates, and after visual analyses of the predicted structures of their complexes with M pro , 17 were chosen for evaluation in a kinetic assay for M pro inhibition. Remarkably 14 of the compounds at 100-μM concentration were found to reduce the enzymatic activity and 5 provided IC 50 values below 40 μM: manidipine (4.8 μM), boceprevir (5.4 μM), lercanidipine (16.2 μM), bedaquiline (18.7 μM), and efonidipine (38.5 μM). Structural analyses reveal a common cloverleaf pattern for the binding of the active compounds to the P1, P1’, and P2 pockets of M pro . Further study of the most active compounds in the context of COVID-19 therapy is warranted, while all of the active compounds may provide a foundation for lead optimization to deliver valuable chemotherapeutics to combat the pandemic.
Open AccessIdentification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
A consensus virtual screening protocol has been applied to ca. 2000 approved drugs to seek inhibitors of the main protease (M pro ) of SARS-CoV-2, the virus responsible for COVID-19. 42 drugs emerged as top candidates, and after visual analyses of the predicted structures of their complexes with M pro , 17 were chosen for evaluation in a kinetic assay for M pro inhibition. Remarkably 14 of the compounds at 100-μM concentration were found to reduce the enzymatic activity and 5 provided IC 50 values below 40 μM: manidipine (4.8 μM), boceprevir (5.4 μM), lercanidipine (16.2 μM), bedaquiline (18.7 μM), and efonidipine (38.5 μM). Structural analyses reveal a common cloverleaf pattern for the binding of the active compounds to the P1, P1’, and P2 pockets of M pro . Further study of the most active compounds in the context of COVID-19 therapy is warranted, while all of the active compounds may provide a foundation for lead optimization to deliver valuable chemotherapeutics to combat the pandemic.